Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Combination Treatment With Everolimus, Letrozole and Trastuzumab in Hormone Receptor and HER2/Neu-Positive Patients With Advanced Metastatic Breast Cancer and Other Solid Tumors: Evaluating Synergy and Overcoming Resistance

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02152943
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:37:53.201083+00:00
Published At
2020-12-19T00:00:00+00:00
Record Updated At
2020-12-19
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Advanced Malignant Solid Neoplasm", "Estrogen Receptor Positive", "HER2/Neu Positive", "Postmenopausal", "Premenopausal", "Progesterone Receptor Positive", "Recurrent Breast Carcinoma", "Refractory Breast Carcinoma", "Refractory Hormone Receptor Positive Breast Carcinoma", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIC Breast Cancer AJCC v7", "Stage IV Breast Cancer AJCC v6 and v7"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2020-12-19"
protocolSection.identificationModule.nctId
"NCT02152943"
protocolSection.identificationModule.officialTitle
"Combination Treatment With Everolimus, Letrozole and Trastuzumab in Hormone Receptor and HER2/Neu-Positive Patients With Advanced Metastatic Breast Cancer and Other Solid Tumors: Evaluating Synergy and Overcoming Resistance"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Advanced Malignant Solid Neoplasm (protocolSection.conditionsModule.conditions)
  • Estrogen Receptor Positive (protocolSection.conditionsModule.conditions)
  • HER2/Neu Positive (protocolSection.conditionsModule.conditions)
  • Postmenopausal (protocolSection.conditionsModule.conditions)
  • Premenopausal (protocolSection.conditionsModule.conditions)
  • Progesterone Receptor Positive (protocolSection.conditionsModule.conditions)
  • Recurrent Breast Carcinoma (protocolSection.conditionsModule.conditions)
  • Refractory Breast Carcinoma (protocolSection.conditionsModule.conditions)
  • Refractory Hormone Receptor Positive Breast Carcinoma (protocolSection.conditionsModule.conditions)
  • Stage IIIA Breast Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IIIB Breast Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IIIC Breast Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IV Breast Cancer AJCC v6 and v7 (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.